Relationship Between Cytogenetic Complexity and Peritumoral Edema in High-Grade Astrocytoma

Kyung-Ho Jeong, M.D.1, Young-Jin Song, M.D.1,2, Jin-Yeong Han, M.D.3, and Ki-Uk Kim, M.D.1,2
Departments of Neurosurgery1, Brain Tumor Institute2, Medical Science Research Center, Department of Laboratory Medicine3, College of Medicine, Dong-A University, Busan, Korea

Background: The purpose of the study is to reveal the association of cytogenetic complexity and peritumoral edema volume (PTEV) and its prognostic significance in high-grade astrocytoma patients by culturing patient tumor cells.

Methods: Twenty-seven high-grade astrocytoma patients were divided into three groups according to karyotype complexity: normal, non-complex karyotype (NCK), and complex karyotype (CK). Endothelial growth factor receptor (EGFR) amplification was detected by FISH, and its association with chromosome 7 abnormalities was analyzed. Mean PTEV of each group was compared by ANOVA to evaluate the relationship between PTEV and cytogenetic complexity.

Results: The PTEV of patients in normal (n=6), NCK (n=8), and CK (n=13) groups were 24.52±17.73, 34.26±35.04, and 86.31±48.7 cm³, respectively (P=0.005). Ten out of 11 patients with EGFR amplification showed abnormalities in chromosome 7. The mean PTEV of EGFR-amplified and non-amplified groups were 80.4±53.7 and 41.3±37.9 cm³, respectively (P=0.035). The average survival of patients with PTEV less than 90 cm³ was 30.52±26.11 months, while in patients with PTEVs over or equal to 90 cm³, it was 10.83±5.53 months (P=0.007).

Conclusions: The results show an association of complex karyotype with the PTEV of high-grade astrocytoma. EGFR amplification plays a significant role in the formation of peritumoral edema, causing PTEV to increase, which is related with survival. This implies that cytogenetic karyotype can be applied as a prognostic factor.

Key Words: High-grade astrocytoma, Chromosome, EGFR amplification, Peritumoral edema

INTRODUCTION

High-grade astrocytomas are the most common, and the most fatal, primary brain tumors, which occur in adults around the age of 50 yr [1, 2]. Currently, the mean survival is 14.6 months for patients treated with temozolomide combined with radiotherapy, with a 2-yr survival rate of 26.5%, which has been slightly increasing over recent decades [3]. A number of investigations on prognostic factors are ongoing [2, 4]. Intratumoral cytogenetic expression and radiological characteristics are also well-known factors that influence patient outcomes [5-14].

During investigation of prognostic factors related to karyotype in high-grade astrocytoma patients in our hospital, the peritumoral edema volume (PTEV) of the patients seemed to increase when the karyotype become more complex. Therefore, we further analyzed the relationship between cytogenetic complexity and PTEV.

In 2005, Lopez-Gines et al [14] reported that polysomy of chromosome 7 is related to EGFR amplification. Receptors such as vascular endothelial growth factor (VEGF), EGFR, and plate-
let-derived growth factor receptor (PDGFR) are factors associated with vascular permeability and angiogenesis, which play a significant role in the formation of peritumoral edema (PTE) [15, 16]. This EGFR mutation, which is related to chromosome 7 polysomy, could increase vascular permeability, finally leading to the expansion of PTE. A large proportion of patients in our study showed abnormalities in chromosome 7 along with EGFR amplification, suggesting a possible linkage between genetic complexity and PTE.

PTE, usually detected by initial radiological evaluation, has been reported as a significant prognostic factor. Schoenegger et al [17] suggested to classify patients into two groups, minor (< 1 cm) and major edema (≥1 cm), according to the largest diameter of edema upon magnetic resonance imaging (MRI). They reported that patients with major edema showed significantly shorter survival compared with patients with minor edema.

Revealing associations between cytogenetic complexity, EGFR amplification, and PTEV could possibly help physicians determine the prognosis of the patients more precisely, considering abnormalities in chromosome 7 and EGFR amplification in high-grade astrocytoma.

3. Karnofsky Performance Score and survival duration
KPS of the patients was evaluated preoperatively, postoperatively, and at three months after discharge. The survival duration was measured in months from the first diagnosis of the disease to the expiration of the patient.

4. Genetic analysis
Karyotype analysis was performed on short-term cultures (3-8 days) established from cells of surgically removed tumors. Tissue was selected by a skilled pathologist under sterile conditions, providing specimens without necrosis and more than 90% tumor tissue. Specimens were cultured and processed. Slides were stained with trypsin and Leishman’s buffered solution for GLT-bandung. The karyotypes were classified according to the International System for Human Cytogenetic Nomenclature (ISCN 2013).

An abnormal karyotype was defined as the results other than 46, XY or 46, XX. Cytogenetic complexity was classified according to the number of independent aberrations in one metaphase. If there were three or more independent aberrations, that specimen was categorized in the complex karyotype (CK) group. Samples with less than three aberrations were categorized in the non-complex karyotype (NCK) group.

5. EGFR amplification
FISH was performed on the Tissue Microarray (TMA) samples. Paraffin blocks were cut into 4-μm-thick sections. Sections were deparaffinized by xylene, incubated with 0.3% pepsin in 10 mM HCl at 37°C for 10 min, boiled with citrate buffer (pH 6.0) in a microwave, incubated in 1M NaSCN for 35 min at 80°C, immersed in pepsin solution, and then fixed in 10% neutral buffered formalin. LSI EGFR/Chromosome enumeration probe (CEP)7 dual-color probe sets (Abbott Molecular, Des Plaines, IL, USA) were used for determining EGFR gene status. We applied the probe mixture to the slides and incubated the slides in a humidified atmosphere with HYBrite (Abbott Molecular) at 73°C for 5 min for simultaneous denaturation of the probe and target DNA. Then, we changed the temperature to 37°C for 19 hr to hybridize the probe and target DNAs. The slides were soaked in 0.4×SSC/0.3% NP-40 for 2 min at room temperature, followed by 2×SSC/0.1% NP-40 for 5 min at 73°C. Non-overlapping intact nuclei (100) were counted. EGFR FISH was performed by using previously published methods [18]. Amplification was applied only for EGFR hybridization and required that the overall mean EGFR/CEP7 ratio must be 1.2 or more and that 10% or more of nuclei had more than three EGFR signals.
## Table 1. Characteristics of study participants

| Sex | Age | Genetic Complexity | Chromosomal results | SurD (mo) | Size (cm³) | EGFR amplification |
|-----|-----|---------------------|---------------------|----------|-----------|-------------------|
| M   | 64  | Normal              | 46, XY              | 54       | 39        | 7.34              | 31.66 (-) |
| M   | 22  | Normal              | 46, XY              | 42       | 110.14    | 82.68             | 27.46 (+) |
| F   | 54  | Normal              | 46, XX              | 20       | 106.76    | 55.47             | 51.29 (-) |
| F   | 55  | Normal              | 46, XX              | 110      | 6.381     | 6.01              | 0.371 (-) |
| F   | 33  | Normal              | 46, XX              | 18       | 54.34     | 28.08             | 26.26 (-) |
| F   | 70  | Normal              | 46, XX              | 11       | 55.68     | 45.61             | 10.07 (-) |
| F   | 70  | NCK                 | 45,X,-X[13]/46,XX[7]| 19       | 15.55     | 14.21             | 1.338 (-) |
| M   | 55  | NCK                 | 45,X,-Y[20]         | 23       | 160.65    | 116.1             | 44.55 (-) |
| F   | 49  | NCK                 | 45,X,-X[3]/46,XX[17]| 24       | 101.11    | 42.49             | 58.61 (-) |
| M   | 44  | NCK                 | 45,X,-Y[5]/46,XX[15]| 11       | 0.95      | 0.841             | 0.109 (-) |
| M   | 45  | NCK                 | 45,X,-Y[10]/46,XX[10]| 19      | 90.24     | 84.92             | 5.327 (-) |
| M   | 52  | NCK                 | 45,X,-Y[13]/46,XX[7]| 54       | 144.26    | 73.33             | 70.92 (-) |
| F   | 77  | NCK                 | 47,XX,+12(2)/46,XX[11]| 18      | 102.03    | 15.67             | 86.36 (-) |
| M   | 73  | NCK                 | 45,X,-Y[27]         | 8        | 17.55     | 10.69             | 6.86 (-)  |
| F   | 44  | CK                  | 45,X,-X[5]/48,XX,+X,+7[2]/46,XX[13]| 59     | 170.88    | 111.4             | 59.48 (+)  |
| M   | 66  | CK                  | 50,XY, dic(1;4)(p13;q55),+5,+7,+7,del(7)(p15),add(9)(p24),add(17)(q25),add(19)(p13),+mar[20]| 9      | 223.25    | 61.15             | 162.1 (+)  |
| M   | 44  | CK                  | 40,XY,-1,der(3)(t3;13)(q21;p24),+7,-8,der(9)(t9;22)(q10;q10),del(10)(H10;10)(p10;q10),-13,-14,-16,-17,-22/24/46,XY[18]| 10     | 114.97    | 97.39             | 17.58 (+)  |
| F   | 48  | CK                  | 47,XX,+X,der(4)(q10),+7,+7,-10,add(17)(q25),-19,+20,-22/20| 44     | 111.71    | 30.33             | 81.38 (+)  |
| M   | 54  | CK                  | 40~42,XY,-1,der(3)(t1;13)(p13;q11.2),del(2)(p12),-5,add(6)(q25),-8,-9,-9,-11,add(11)(q23),-12,add(13)(q34),-14,add(19)(q13.3),del(22)(q13),+4,-6mar(np17)/46,XY[3]| 12     | 112.08    | 18.56             | 93.51 (+)  |
| M   | 57  | CK                  | 45,X,-Y[22]/39~49,XY,-3,+7,der(8)(t3;8)(q13.1;q24.3)+,9,+r(?),+mar[cp3]| 13     | 86.89     | 51.36             | 35.53 (+)  |
| M   | 30  | CK                  | 47,XY,+Y[5]/47,idem,-1,add(4)(p16),add(5)(p15.3),del(6)(p25),t(7;14)(q11.2;q21),der(11)(t11;11)(p32;q23),der(15)(t15;15)(q22),add(16)(q24),del(17)(q23),+mar[15]| 67     | 66.77     | 7.228             | 59.54 (+)  |
| F   | 47  | CK                  | 78~84,XXXX,-6,-6,+7,-8,-8,del(9)(p23)x2,-10,-10,der(12q)x2,-14,-14,-17,add(19q)x2,add(22q)x2,cp[11]/41~43,XX,-6,+7,-8,del(9)(p23),-10,der(12q)x2,-14,-17,add(19q)x2,add(22q)x2,cp[9]| 10     | 89.36     | 52.45             | 36.91 (+)  |
| F   | 63  | CK                  | 70~72,XX,-X,-X,+,+2,del(4)(q31.3),+5,del(6)(q21),del(7)(p17),add(15)(q17),add(19)(q17),del(22)(q18),add(22)(q24),del(22)(q23),+mar[15]| 16     | 172.32    | 8.34              | 163.98 (+) |
| M   | 46  | CK                  | 46,XY,t(1;13)(p12;q32),der(17;19y)+9/46(X)[2]| 6       | 214.73    | 92.04             | 122.7 (-)  |
| M   | 73  | CK                  | 45,X,-Y[11]t(1;14)(p36.3;q27),del(10)(q23)(3)/46,XY[7]| 7       | 57.13     | 7                 | 50.13 (-)  |
| M   | 72  | CK                  | 65~79,add(X)(q28),+add(X)(q28),+Y,+1,+2,+3,+3,+4,+5,+6,del(6)(q21)x2,+7,+7,+8,+add(9)(p21),+11,+12,+12,+15,+16,+16,+16,+17,+add(17)(p11.2)x2,+18,+19,+19,+20,+20,+20,+20,+mar[cp20]| 4      | 170.16    | 34.71             | 135.45 (+) |
| M   | 29  | CK                  | 47,XY,-7,del(18)(t7;18)(p13;q21),+2mar(5)/46,XY,inv(1)(p32q22),t(2;15)(p12;p26),t(5;16)(q13;p13),t(12;18)(q22;q12)(4)/46,XY,t(2;13)(p23;q34),t(5;7)(q31;p22)(4)/46,XY,t(1;15)(p35;p13),t(2;4)(p25;q21),del(9)(p12)(22)/46,XY[5]| 18     | 132.35    | 27.06             | 105.29 (+) |

Abbreviations: SurD, survival duration; mo, months; Tot, total; Tm, tumor; Ed, edema; EGFR, Endothelial growth factor receptor; NCK, non-complex karyotype; CK, complex karyotype.
6. Radiologic analysis
In addition, the size of PTE at the initial MRI of each patient was measured. The observer was blinded to molecular analysis results, and the subtraction of T2-FLAIR volume to the enclosed T1-enhancing volume was calculated. The high signal of T2-FLAIR images represents the total volume of tumor mass and PTE, and the enhanced margin in T1-enhancing images is considered the tumor mass itself. Each volume was manually measured by adding the region of interest (ROI) areas of each MRI slide. For further analysis of edema volume compared with tumor mass volume, the edema ratio was calculated by dividing tumor volume from edema volume.

7. Statistics
For statistical analyses, SPSS software (version 18.0; SPSS Inc., Chicago, IL, USA) was used. For evaluating relationship between cytogenetic abnormalities and various clinical factors (except for survival), a t-test was applied. Chi-square cross analysis was performed to determine the relationship between chromosome 7 abnormalities and EGFR amplification. For analysis with three variables, such as normal, NCK, and CK group comparisons, ANOVA was performed. The Kaplan-Meier method was applied to estimate survival as a function of time, and survival differences were analyzed by the log-rank test. For all statistical analyses, P values less than 0.05 were considered significant.

RESULTS

1. Chromosomal analysis
Among the 27 high-grade astrocytoma patients, 22 glioblastoma multiforme (GBM) and 5 anaplastic astrocytomas were identified. There were 16 and 11 male and female patients. The size of edema in the normal (n=6) and abnormal (n=21) chromosome groups were 24.52±17.73 cm³ and 66.48±50.23 cm³ (P=0.004), respectively, while the survival duration was 42.5±36.84 months in the normal group and 21.48±18.37 months in the abnormal group (P=0.129). The size of tumor mass, pre-op KPS, or post-op KPS showed no relationship to patients’ karyotype.

The subjects were further classified into three groups of normal, NCK, and CK in terms of the cytogenetic complexity. The number of patients in each group was six, eight, and 13, respectively. The mean edema size was 24.52±17.73 cm³ in the normal chromosome group, 34.26±35.04 cm³ in the NCK group, and 86.31±48.7 cm³ in the CK group (P=0.005) (Table 2).

2. EGFR amplification
Eleven out of 27 patients showed EGFR amplification. Ten out of these 11 EGFR amplification-positive patients showed abnormalities in chromosome 7 (90.9%). Abnormalities in chromosome 7 were mostly polysomies, one case of derivative chromosome by 7p12 translocation and one case of monosomy. The mean PTEVs of patients with or without EGFR amplification were 80.4±53.7 cm³ and 41.3±37.9 cm³ (P=0.035), respectively. However, there was no significant difference in mean survival (Table 3).

3. Peritumoral edema
Although the association of survival duration and PTE has been established, the exact criterion for measurement has not been determined. Therefore, various statistical analysis approaches have been attempted to generate a meaningful standard for examining PTE. One such attempt was to search for the significant standard edema volume, which is done by calculating the difference in mean survival after dividing patients into two groups by altering standards every 10 cm³ from 50 cm³ to 100 cm³.

Table 2. Survival duration, tumor and edema size, pre-op KPS, and post-op KPS according to cytogenetic complexity

|                      | Normal (n=6) | NCK (n=8) | CK (n=13) | P value |
|----------------------|-------------|-----------|-----------|---------|
| Survival duration (months) | 42.5±36.84 | 22±14.04 | 21.15±21.14 | 0.293   |
| Total volume (cm³) | 62.05±40.11 | 79.05±60.91 | 132.39±53.73 | 0.022   |
| Tumor volume (cm³) | 37.53±29.73 | 44.78±42.08 | 46.08±35.67 | 0.891   |
| PTEV (cm³) | 24.52±17.73 | 34.26±35.04 | 86.31±48.7 | 0.005   |
| Edema ratio | 1.13±1.6 | 1.15±1.82 | 4.36±5.26 | 0.125   |
| pre-op KPS | 85±5.48 | 83.75±7.44 | 76.15±16.09 | 0.247   |
| post-op KPS | 73.33±22.51 | 76.25±16.85 | 73.08±14.37 | 0.912   |

Data are presented as mean±standard deviation. Edema ratio=Peritumoral edema volume/Tumor volume. Abbreviations: KPS, Karnofsky Performance Score; NCK, non-complex karyotype; CK, complex karyotype; PTEV, peritumoral edema volume.
The significance of the relationship between PTEV and survival was maximized when the standard edema volume was 90 cm$^3$.

The average survival of patients with PTEV less than 90 cm$^3$ was 30.52±26.11 months. On the other hand, the survival of patients with PTEV of 90 cm$^3$ or greater was 10.83±5.53 months ($P=0.007$) (Fig. 1).

Since the mean PTEV of the EGFR-amplified and CK groups were 80.4±53.7 cm$^3$ and 86.31±48.7 cm$^3$, respectively, the survival of patients with the standard edema volume of 80 cm$^3$ were also investigated. The mean survival duration of patients with PTEV less than 80 cm$^3$ was 31.15±26.63 months. On the other hand, patients with PTEV at 80 cm$^3$ or greater was 11.86±5.73 months ($P=0.052$).

However, the edema ratio did not show any relevance to survival or chromosomal results.

**DISCUSSION**

High-grade astrocytomas, including anaplastic astrocytoma and glioblastoma, are the most common primary brain tumors [1, 2]. They are known as some of the most devastating malignancies because of their poor survival rates, mostly occurring in adults around the age of 50 yr. The age of patients in our study ranged from 22 to 77 yr (mean 53.19±13.72 yr) [1]. The mean survival of our patients was 26.15 months with a two-year survival rate of 25.9%. It is possible that the long mean survival rate observed is because of the exclusion criteria of this study.

Since patients’ lives are threatened from the moment of their diagnosis, numerous trials have been conducted and are still ongoing to determine more precise prognosis or progression of the glioblastoma.

The purpose of this study was to clarify the association of intratumoral cytogenetic abnormalities and radiological characteristics, which could possibly be significant prognostic factors [4, 11, 19-21]. Specifically, the relationship between karyotype complexity and PTEV was the focus of our study.

The mean PTEV of normal chromosome patients was 24.52 cm$^3$, while the mean PTEV of the abnormal group was 66.48 cm$^3$ ($P=0.004$). Among the abnormal karyotype patients, the CK group showed significantly larger PTEV than the NCK group, with mean PTEVs of 34.26±35.04 cm$^3$ and 86.31±48.7 cm$^3$ ($P=0.005$), respectively. This implies that karyotype complexity is associated with PTEV.

This PTE is a widely known prognostic factor of high-grade astrocytoma. Schoeneggar et al [17] suggested classifying patients into either minor (<1 cm) or major edema (≥1 cm) according to the largest edema diameter as determined using MRI. However, we focused on investigating the possibility of dividing patients into minor and major edema groups according to the three-dimensional volume. The mean edema size of total candidates was 57.16 cm$^3$. Through statistical analysis, we determined that when the standard volume was set as 90 cm$^3$, the relationship between PTEV and survival was significant. The mean survival duration of patients with PTEV less than 90 cm$^3$ was 30.52 months, and survival of patients with PTEV 90 cm$^3$ or greater was 10.83 months ($P=0.007$). This suggests PTE is a meaningful prognostic factor, which brings edema control as a critical issue during the treatment of malignant astrocytoma (Fig. 2).

There have been attempts to link image features with gene expression modules, which allows prediction of the clinical and molecular characteristics of tumors noninvasively [22]. Well-known instances of molecular prognostic factors are 1p/19q
chromosomal codeletion, O⁶-methylguanin-DNA-methyltransferase (MGMT) promoter methylation, isocitrate dehydrogenase (IDH) mutations, and EGFR amplification [7, 12, 15, 23]. The samples in this study were also subjected to different sorts of molecular analyses, such as staining of glial fibrillary acidic protein (GFAP), p53, EGFR, PDGFR, and other components [11, 13, 24]. Among them, our study concentrated on EGFR amplification, one of the molecular factors dealing with vascular permeability, and its relationship with PTEV in high-grade astrocytoma patients [6]. All patients with abnormalities in chromosome 7 showed EGFR amplification. Considering the fact that the chromosomal locus of EGFR is 7p12, there was a significant relationship. On the other hand, among patients with EGFR mutation, 90.9% showed monosomy, polysomy, or translocation in chromosome 7. The mean PTEV of patients with or without EGFR amplification was 80.4 cm³ and 41.3 cm³ (P=0.035), respectively, implying that abnormalities in chromosome 7 or EFGR amplification could affect PTEV, and this mostly takes place in CK patients (Fig. 3).

The study has its significance in the first attempt in Korea to reveal the relationship between chromosomal abnormalities and radiologic findings in malignant astrocytoma patients by culturing tumor cells. However, the relationship between chromosomal abnormality and survival duration in our study was relatively low according to Kaplan-Meier survival curve (P=0.293), which may be due to other significant prognostic factors such as age, KPS, and VEGF levels. Therefore, more precise results may be achieved with a further investigation on a larger number of candidates.

For a comprehensive interpretation of this study, the cytogenetic complexity of high-grade astrocytoma could lead to amplification of the EGFR gene, which could provoke the enlargement of PTEV due to abnormal angiogenesis. In addition, even with a limited number of patients, it was shown that increased PTEV was related with shorter survival duration. Therefore, a multi-center, prospective plan regarding the prognostic effects of genetic factors and their relationship with radiologic findings should be conducted.
Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgments

This study was supported by the Dong-A University fund.

REFERENCES

1. Ohgaki H and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89.
2. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462-6.
3. Walid MS. Prognostic factors for long-term survival after glioblastoma. Perm J 2008;12:45-8.
4. Barker FG 2nd, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:410-8.
5. Schoenegger K, Oberndorfer S, Wuschitz B, Struhal W, Hainfellner J, Prayr D, et al. Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol 2009;16:874-8.
6. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56.
7. Lawrence YR, Mishra MV, Werner-Wasik M, Andrews DW, Showalter TN, Glass J, et al. Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer 2012;118:4228-34.
8. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:860-6.
9. Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, et al; German Glioma Network. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 2013;19:5146-57.
10. Huir H, Jung S, Jung TY, Kim SY. Cerebellar glioblastoma multiforme in an adult. J Korean Neurosurg Soc 2008;43:194-7.
11. Jain R, Poisson L, Narang J, Gutman D, Scarpace L, Hwang SN, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology 2013;267:212-20.
12. Montgomery RM, Queiroz Lde S, Rogério F, EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. Arq Neuropsiquiatr 2015;73:561-8.
13. Shiraiishi S, Tada K, Nakamura H, Makino K, Kochi M, Saya H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer 2002;95:249-57.
14. Lopez-Gines C, Cerda-Nicolás M, Gil-Benso R, Pellin A, Lopez-Guerrero JA, Callaghan R, et al. Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme. Clin Neuropathol 2005;24:209-18.
15. Reardon D, Wen P, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol 2014;16 (S8):vii7-13.
16. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002;62:3335-9.
17. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-8.
18. Maire CL and Ligon KL. Molecular pathologic diagnosis of epidermal growth factor. Neuro Oncol 2014;16(S8):vii1-6.
19. Maity A, Pore N, Lee J, Solomon D, O’Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-86.